Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based virtual screening: an overview.

Paul D Lyne1

  • 1AstraZeneca R&D Boston, Waltham, MA 02451, USA. paul.lyne@astrazeneca.com

Drug Discovery Today
|January 28, 2003
PubMed
Summary

Genomics advances drive demand for target validation. Receptor-based virtual screening offers a reliable, cost-effective method for identifying drug lead candidates, impacting the discovery process.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of (2<i>R</i>)-<i>N</i>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<i>H</i>-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.

Journal of medicinal chemistry·2020
Same author

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

Cancer research·2018
Same author

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.

PloS one·2018
Same author

Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.

Bioorganic & medicinal chemistry letters·2018
Same author

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors.

Journal of medicinal chemistry·2018
Same author

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Science translational medicine·2017

Area of Science:

  • Computational chemistry and drug discovery.

Background:

  • Genomic advancements have significantly expanded the landscape of potential therapeutic targets.
  • This expansion necessitates robust target validation and efficient methods for identifying lead candidates.

Purpose of the Study:

  • To discuss the current capabilities and limitations of virtual screening technology.
  • To emphasize the workflow of a virtual screening campaign, from initial preparation to post-screening analysis.

Main Methods:

  • Receptor-based virtual screening as a key computational technique.
  • Analysis of the virtual screening workflow, including preparation and post-screening analysis.

Main Results:

  • Virtual screening is presented as a reliable and inexpensive approach for lead identification.
  • Advances in computational techniques are enhancing the impact of virtual screening on drug discovery.

Conclusions:

  • Virtual screening, particularly receptor-based methods, is a valuable tool in modern drug discovery.
  • Understanding the complete workflow is crucial for maximizing the effectiveness of virtual screening campaigns.

Related Experiment Videos